136 related articles for article (PubMed ID: 35252208)
1. Signaling Dynamics of TSHR-Specific CAR-T Cells Revealed by FRET-Based Biosensors.
Zhou J; Chen J; Huang Y; Gao X; Zhou C; Meng X; Sun J
Front Cell Dev Biol; 2022; 10():845319. PubMed ID: 35252208
[TBL] [Abstract][Full Text] [Related]
2. CAR-T Cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer.
Li H; Zhou X; Wang G; Hua D; Li S; Xu T; Dong M; Cui X; Yang X; Wu Y; Cai M; Liao X; Zhang T; Yang Z; Du Y; Li X
J Clin Endocrinol Metab; 2022 Mar; 107(4):1110-1126. PubMed ID: 34751400
[TBL] [Abstract][Full Text] [Related]
3. TSHR-based chimeric antigen receptor T cell specifically deplete auto-reactive B lymphocytes for treatment of autoimmune thyroid disease.
Duan H; Jiang Z; Chen L; Bai X; Cai H; Yang X; Huang H
Int Immunopharmacol; 2023 Nov; 124(Pt A):110873. PubMed ID: 37690235
[TBL] [Abstract][Full Text] [Related]
4. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer.
Ding J; Li D; Liu X; Hei H; Sun B; Zhou D; Zhou K; Song Y
Exp Hematol Oncol; 2022 Sep; 11(1):59. PubMed ID: 36138444
[TBL] [Abstract][Full Text] [Related]
6. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN
Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371
[TBL] [Abstract][Full Text] [Related]
7. Integration of FRET and sequencing to engineer kinase biosensors from mammalian cell libraries.
Liu L; Limsakul P; Meng X; Huang Y; Harrison RES; Huang TS; Shi Y; Yu Y; Charupanit K; Zhong S; Lu S; Zhang J; Chien S; Sun J; Wang Y
Nat Commun; 2021 Aug; 12(1):5031. PubMed ID: 34413312
[TBL] [Abstract][Full Text] [Related]
8. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia.
Zhao X; Yang J; Zhang X; Lu XA; Xiong M; Zhang J; Zhou X; Qi F; He T; Ding Y; Hu X; De Smet F; Lu P; Huang X
Mol Ther Oncolytics; 2020 Sep; 18():272-281. PubMed ID: 32728615
[TBL] [Abstract][Full Text] [Related]
10. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
11. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.
Priceman SJ; Gerdts EA; Tilakawardane D; Kennewick KT; Murad JP; Park AK; Jeang B; Yamaguchi Y; Yang X; Urak R; Weng L; Chang WC; Wright S; Pal S; Reiter RE; Wu AM; Brown CE; Forman SJ
Oncoimmunology; 2018; 7(2):e1380764. PubMed ID: 29308300
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells.
Phanthaphol N; Somboonpatarakun C; Suwanchiwasiri K; Chieochansin T; Sujjitjoon J; Wongkham S; Maher J; Junking M; Yenchitsomanus PT
Front Oncol; 2021; 11():657868. PubMed ID: 33763382
[TBL] [Abstract][Full Text] [Related]
13. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
14. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
Front Immunol; 2020; 11():539654. PubMed ID: 33281809
[TBL] [Abstract][Full Text] [Related]
15. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
16. Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.
Neumann S; Krieger CC; Gershengorn MC
Eur Thyroid J; 2020 Dec; 9(Suppl 1):59-65. PubMed ID: 33511086
[TBL] [Abstract][Full Text] [Related]
17. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells.
Wang Y; Zhong K; Ke J; Chen X; Chen Y; Shu W; Chen C; Hu S; Sun X; Huang H; Luo C; Liu L; Yang J; Zhang Y; Zhi H
Cytotherapy; 2021 Aug; 23(8):715-723. PubMed ID: 33863641
[TBL] [Abstract][Full Text] [Related]
18. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.
Guercio M; Orlando D; Di Cecca S; Sinibaldi M; Boffa I; Caruso S; Abbaszadeh Z; Camera A; Cembrola B; Bovetti K; Manni S; Caruana I; Ciccone R; Del Bufalo F; Merli P; Vinti L; Girardi K; Ruggeri A; De Stefanis C; Pezzullo M; Giorda E; Scarsella M; De Vito R; Barresi S; Ciolfi A; Tartaglia M; Moretta L; Locatelli F; Quintarelli C; De Angelis B
Haematologica; 2021 Apr; 106(4):987-999. PubMed ID: 32381575
[TBL] [Abstract][Full Text] [Related]
19. A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq.
Boroughs AC; Larson RC; Marjanovic ND; Gosik K; Castano AP; Porter CBM; Lorrey SJ; Ashenberg O; Jerby L; Hofree M; Smith-Rosario G; Morris R; Gould J; Riley LS; Berger TR; Riesenfeld SJ; Rozenblatt-Rosen O; Choi BD; Regev A; Maus MV
Mol Ther; 2020 Dec; 28(12):2577-2592. PubMed ID: 32755564
[TBL] [Abstract][Full Text] [Related]
20. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
[Next] [New Search]
